1. Who Will Benefit from Charged-Particle Therapy?
- Author
-
Hong Gyun Wu and Kyung Su Kim
- Subjects
Organs at Risk ,Cancer Research ,medicine.medical_specialty ,Proton beam therapy ,medicine.medical_treatment ,Cost-Benefit Analysis ,Heavy Ion Radiotherapy ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Special Article ,0302 clinical medicine ,Eloquent cortex ,Neoplasms ,medicine ,Humans ,heterocyclic compounds ,Carbon-ion radiotherapy ,Radiation Injuries ,Photons ,business.industry ,Incidence ,Patient Selection ,Charged-particle therapy ,Pediatric cancer ,Charged particle ,Radiation therapy ,Treatment Outcome ,Oncology ,Clinical evidence ,030220 oncology & carcinogenesis ,Carbon Ion Radiotherapy ,Radiology ,business - Abstract
Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages compared to conventional photon radiotherapy. As it can reduce the amount of radiation irradiated in the normal organ, CPT has been mainly applied to pediatric cancer and radioresistent tumors in the eloquent area. Although there is a possibility that more patients can benefit from it, high set-up cost and dearth of high level of clinical evidence hinders wide spread of CPT. This review aims to present recent clinical results of PBT and CIRT in selected diseases focusing on possible indications of CPT. We also discussed how clinical studies are conducted to increase the number of patients who can benefit from CPT considering the high cost of it.
- Published
- 2021